Registry update — unassessed
Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTN=34Routine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 15, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This is a protocol abstract without reported outcomes; no efficacy conclusions can be drawn from it. The small sample size (n=34) means any pilot results would have poor statistical power to detect meaningful treatment effects. The trial does not report whether fisetin actually reduced senescent cell burden or whether any changes in senescent markers correlated with functional improvement.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 34
- Duration
- —
- Population
- People with peripheral artery disease (PAD)
- Primary outcome
- Reduction in abundance of senescent cells in blood, skeletal muscle, and subcutaneous and inter muscular adipose tissue; improvement in 6-minute walk distance
- Effect size
- —
- Significance
- Not reported
- Journal
- Northwestern University
- Published
- Apr 15, 2026
Sources
Primary source
- Northwestern University ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD).
the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.